| Dr Andrew Price Howard Iii, PHARMD | |
|
7710 Clifton Way, Mobile, AL 36619-3654 | |
| (251) 377-3489 | |
| Not Available |
| Full Name | Dr Andrew Price Howard Iii |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 7710 Clifton Way, Mobile, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134765795 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 21190 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Price Howard Iii, PHARMD 7710 Clifton Way, Mobile, AL 36619-3654 Ph: (251) 377-3489 | Dr Andrew Price Howard Iii, PHARMD 7710 Clifton Way, Mobile, AL 36619-3654 Ph: (251) 377-3489 |
News Archive
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
While stem-cell therapy offers great promise for the treatment of stroke, much research remains to be done to show its long-term effectiveness and to understand the potential for dangerous side effects.
Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
The body's natural inflammatory response is an essential reaction to injury and infection. When acute inflammation escalates out of control, such as in sepsis, it causes nearly 10% of deaths in the U.S. and more than $17 billion in healthcare costs each year. A group of researchers have developed a groundbreaking biohybrid device that can control acute inflammation to prevent sepsis and other related life-threatening complications, as described in an article in the inaugural issue of Disruptive Science and Technology.
› Verified 5 days ago
Dr. Wilfred Arcard Brown, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1303 Dr Martin L King Jr Ave, Mobile, AL 36603 Phone: 251-436-7702 | |
Chidiya Ohiagu, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1303 Dr Martin L King Jr Ave, Mobile, AL 36603 Phone: 251-432-4117 | |
Darren P Billiot, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6575 Airport Blvd, Mobile, AL 36608 Phone: 251-370-9848 | |
Eric Donaldson Reeves, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4628 Airport Blvd, Mobile, AL 36608 Phone: 251-341-5749 | |
Mr. Chuck P Whisonant, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1504 Spring Hill Ave, Mobile, AL 36604 Phone: 251-219-3754 | |
Ms. Angela F. Amos, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 251 N Bayou St, Mobile, AL 36603 Phone: 251-690-8817 | |
Dr. Raymond Lorenz, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2400 Gordon Smith Dr, Mobile, AL 36617 Phone: 251-450-1388 |